Gleevec was described in Video 2.5 as a drug targeting the BCR-ABL fusion protein, an abnormal kinase encoded by an oncogene on the "Philadelphia chromosome" that is frequently found in chronic myelogenous leukemias. Gleevec is a kinase inhibitor that suppresses BCR-ABL fusion protein activity, and reduces tumor growth rate effectively in many CML patients with a Philadelphia chromosome. However, as with all mutation-targeting chemotherapeutic drugs, the efficacy of Gleevec declines over time in any given patient, and eventually it stops working to suppress tumor growth. Considering what you have learned about genetic changes underlying the formation and progression of tumors, propose an explanation for the decline in efficacy of Gleevec over time. Limit your answer to 1-2 sentences.
Gene Interactions
When the expression of a single trait is influenced by two or more different non-allelic genes, it is termed as genetic interaction. According to Mendel's law of inheritance, each gene functions in its own way and does not depend on the function of another gene, i.e., a single gene controls each of seven characteristics considered, but the complex contribution of many different genes determine many traits of an organism.
Gene Expression
Gene expression is a process by which the instructions present in deoxyribonucleic acid (DNA) are converted into useful molecules such as proteins, and functional messenger ribonucleic (mRNA) molecules in the case of non-protein-coding genes.
For tis question you don't need video 2.5 to answer it. Base on your understanding what will be the best answer to this
Step by step
Solved in 3 steps